ANIDULAFUNGIN
Anidulafungin or Eraxis (Ecalta in Europe) is a semisynthetic echinocandin used as an antifungal drug . Anidulafungin was originally manufactured and submitted for FDA approval by Vicuron Pharmaceuticals.Pfizer acquired the drug upon its acquisition of Vicuron in the fall of 2005.Pfizer gained approval by the Food and Drug Administration (FDA) on February 21, 2006;it was previously known as LY303366. There is preliminary evidence it has a similar safety profile to caspofungin. It has proven efficacy against oesophageal candidiasis, but its main use will probably be in invasive Candida infection; it will probably also have application in treating invasive Aspergillus infection. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)β-D-glucan synthase, which is an important component of the fungal cell wall.
N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)- 6-[(1S,2R)-1,2-dihydroxy- 2-(4-hydroxyphenyl)ethyl]- 11,20,21,25-tetrahydroxy- 3,15-bis[(1R)-1-hydroxyethyl]- 26-methyl- 2,5,8,14,17,23-hexaoxo- 1,4,7,13,16,22-hexaazatricyclo [22.3.0.09,13] heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide
eBioChem.com can offer Anidulafungin， here is the price link：http://www.ebiochem.com/product/anidulafungin-16995
没有评论:
发表评论